Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23956800 | 0.80 | HSD17B10 (0.32) | HSD17B10KEAP1NFE2L2 | |
| SCHEMBL9278494 | 0.80 | HSD17B10 (0.36) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL8368739 | 0.78 | CNR1 (0.37) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL12707754 | 0.77 | KEAP1 (0.38) | HSD17B10KEAP1NFE2L2KMT2A | |
| SCHEMBL10458849 | 0.76 | HSD17B10 (0.34) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL12741104 | 0.75 | KDM4E (0.40) | HSD17B10 | |
| SCHEMBL6286736 | 0.74 | HSD17B10 (0.33) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL20218457 | 0.74 | HSD17B10 (0.35) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL6289597 | 0.74 | HSD17B10 (0.33) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 | |
| SCHEMBL6284942 | 0.74 | HSD17B10 (0.35) | HSD17B10KEAP1NFE2L2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629889-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RES & DEV (IL) | 2019-04-03 | — | — | EP | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | HSD17B10 382/4885KEAP1 538/4885NFE2L2 2915/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | HSD17B10 382/4885KEAP1 538/4885NFE2L2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.